United States - English - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate 0.1 mg

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate 0.1 mg

United States - English - NLM (National Library of Medicine)

mylan institutional inc. - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate 0.2 mg

United States - English - NLM (National Library of Medicine)

apotex corp. - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin nasal spray is indicated as antidiuretic replacement therapy in the management of central diabetes insipidus in adults and pediatric patients 4 years of age and older   limitations of use: desmopressin nasal spray is not indicated for: - treatment of nephrogenic diabetes insipidus, - treatment of primary nocturnal enuresis [see warnings and precautions (5.1)], - use in patients with conditions that compromise the intranasal route of administration (e.g., severe nasal congestion and blockage, nasal mucosa atrophy, severe atrophic rhinitis, recent nasal surgery such as transsphenoidal hypophysectomy) [see warnings and precautions (5.2)]. - use in patients with an impaired level of consciousness, - use in patients requiring doses less than 10 mcg or doses that are not multiples of 10 mcg [see dosage forms and strengths (3)]. desmopressin nasal spray is contraindicated in patients with: - known hypersensitivity to desmopressin acetate or to any of the components of desmopressin nasal spray. severe

United States - English - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin 4 ug in 1 ml

United States - English - NLM (National Library of Medicine)

avadel specialty pharmaceuticals, llc - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate 0.83 ug - noctiva is indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. nocturnal polyuria was defined in the noctiva clinical trials as nighttime urine production exceeding one-third of the 24-hour urine production. before starting noctiva: - evaluate the patient for possible causes for the nocturia, including excessive fluid intake prior to bedtime, and optimize the treatment of underlying conditions that may be contributing to the nocturia. - confirm the diagnosis of nocturnal polyuria with a 24-hour urine collection, if one has not been obtained previously. limitation of use : noctiva has not been studied in patients less than 50 years of age. noctiva is contraindicated in patients with the following conditions due to an increased risk of severe hyponatremia: - hyponatremia or a history of hyponatremia [see warnings and precautions (5.1)] - polydipsia - primary nocturnal enuresis [see use in specific populations (8.4)] - concomitant use with

Canada - English - Health Canada

pharmascience inc - desmopressin acetate (desmopressin acetate trihydrate) - tablet - 0.1mg - desmopressin acetate (desmopressin acetate trihydrate) 0.1mg - pituitary

Canada - English - Health Canada

pharmascience inc - desmopressin acetate (desmopressin acetate trihydrate) - tablet - 0.2mg - desmopressin acetate (desmopressin acetate trihydrate) 0.2mg - pituitary

United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate injection is indicated for patients with hemophilia a with factor viii coagulant activity levels greater than 5%. desmopressin acetate injection will often maintain hemostasis in patients with hemophilia a during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure. desmopressin acetate injection will also stop bleeding in hemophilia a patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. in certain clinical situations, it may be justified to try desmopressin acetate injection in patients with factor viii levels between 2% to 5%; however, these patients should be carefully monitored. desmopressin acetate injection is indicated for patients with mild to moderate classic von willebrand's disease (type i) with factor viii levels greater than 5%. desmopressin acetate injection will often maintain hemostasis in patients with mild to moderate von willebrand's disease during

United States - English - NLM (National Library of Medicine)

teva parenteral medicines, inc. - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate 4 ug in 1 ml - desmopressin acetate injection is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. limitations of use: desmopressin acetate is ineffective and not indicated for the treatment of nephrogenic diabetes insipidus. desmopressin acetate injection is indicated for patients with hemophilia a with factor viii coagulant activity levels greater than 5% without factor viii antibodies to: - maintain hemostasis during surgical procedures and postoperatively - reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. desmopressin acetate injection is indicated for patients with mild to moderate von willebrand’s disease (type i) with factor viii levels greater than 5% to: - maintain hemostasis during surgical procedures and postoperatively - reduce bleeding with episodes of s